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Amyotrophic Lateral Sclerosis (ALS) is an adult-onset and fast progression
neurodegenerative disease that leads to the loss of motor neurons. Mechanisms of
selective motor neuron loss in ALS are unknown. The early events occurring in the spinal
cord that may contribute to motor neuron death are not described, neither astrocytes
participation in the pre-symptomatic phases of the disease. In order to identify ALS
early events, we performed a microarray analysis employing a whole mouse genome
platform to evaluate the gene expression pattern of lumbar spinal cords of transgenic
SOD1G93A mice and their littermate controls at pre-symptomatic ages of 40 and 80 days.
Differentially expressed genes were identified by means of the Bioconductor packages
Agi4×44Preprocess and limma. FunNet web based tool was used for analysis of
over-represented pathways. Furthermore, immunolabeled astrocytes from 40 and 80 days
old mice were submitted to laser microdissection and RNA was extracted for evaluation
of a selected gene by qPCR. Statistical analysis has pointed to 492 differentially expressed
genes (155 up and 337 down regulated) in 40 days and 1105 (433 up and 672 down) in
80 days old ALS mice. KEGG analysis demonstrated the over-represented pathways tight
junction, antigen processing and presentation, oxidative phosphorylation, endocytosis,
chemokine signaling pathway, ubiquitin mediated proteolysis and glutamatergic synapse
at both pre-symptomatic ages. Ube2i gene expression was evaluated in astrocytes from
both transgenic ages, being up regulated in 40 and 80 days astrocytes enriched samples.
Our data points to important early molecular events occurring in pre-symptomatic phases
of ALS in mouse model. Early SUMOylation process linked to astrocytes might account to
non-autonomous cell toxicity in ALS. Further studies on the signaling pathways presented
here may provide new insights to better understand the events triggering motor neuron
death in this devastating disorder.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a fast disabling neu-
rodegenerative disease characterized by upper and lower motor
neuron loss of motor cortex, brainstem, and spinal cord lead-
ing to respiratory insufficiency and death (Turner et al., 2013).
The incidence of ALS ranges from 1.7 to 2.3 cases per 100,000
population per year worldwide (Beghi et al., 2006). The mech-
anisms underlying neurodegeneration in ALS are multifactorial,
and seem to involve neurons and non-neuronal cells (Boillee
et al., 2006a,b; Yamanaka et al., 2008;Wang et al., 2011a) as well as
several molecular pathways (Boillee et al., 2006a; Ferraiuolo et al.,
2011b; Kiernan et al., 2011; Usuki et al., 2012). Approximately
5% of ALS cases are familial, and 20% of these have been linked
to mutations in Cu/Zn superoxide dismutase 1 (SOD1) (Rosen
et al., 1993; Andersen and Al-Chalabi, 2011). The first symptoms
define the beginning of the clinical phase of the diagnosed cases
of the more prevalent sporadic forms, consisting in muscle atro-
phy, weakness, fasciculations, and spasticity (Brooks et al., 2000).
There is a lack of pathological studies on post mortem spinal
cord from ALS patients that could add information about the
triggering, initial time of motor neuron death and mechanisms
of the disease. In fact, Fischer et al. (2004) reported the post-
mortem evaluation in a patient with a short history of ALS,
whose electromyography showed signs of acute and chronic den-
ervation, coming out with an unexpected die without peripheral
and central motor neuron death together with autolytic changes
and a little axonal degeneration. Histological evaluations at the
neuromuscular junctions and also electrophysiological analysis
at the peripheral nerves in ALS patients have allowed authors
to claim that motor neuron death correlates to the begging of
clinical classical symptoms (Veugelers et al., 1996; Liu et al.,
2013).
As the majority of familial ALS cases are linked to the
mutations in SOD1 gene (Dion et al., 2009), transgenic mice
expressing human mutant SOD1 (mSOD1) developing age-
dependent clinical and pathological features of human ALS
are current largely employed in the physiopathological studies
of the disorder (Turner and Talbot, 2008). Using this mouse
model, we previously described early behavior and electro-
physiological alterations, prior the classical neurological symp-
toms and the beginning of motor neuron death (Alves et al.,
2011). In fact, several early events demonstrated in animal
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models seemed to precede the neuronal death, remarkably
the activation of glial cells (microglia and astrocytes) close
to motor neurons (Graber et al., 2010; Wang et al., 2011b;
Gerber et al., 2012), retraction of motor neuron fibers and
neuromuscular junction displacement (Fischer et al., 2004; De
Winter et al., 2006; Narai et al., 2009). It is still unknown
whether the most claimed pathogenic processes for ALS, for
instance oxidative stress, mitochondrial and neurofilament dys-
function, excitotoxicity, inflammation, non-autonomous cell
toxicity, protein misfolding and abnormal RNA processing
(Rothstein et al., 1992; Bergeron et al., 1994; Boillee et al., 2006a;
Lemmens et al., 2010; Bendotti et al., 2012; Richardson et al.,
2013) are taking place at the pre-symptomatic period of the
disease.
The central question in understanding ALS facing thera-
peutic target development involves a further knowledge about
the toxic mechanisms that trigger motor neuron death (Boillee
et al., 2006a). Until scientific technology approaches do not
overstep ethical limitations of clinical studies, the mutant SOD1-
expressing mouse model may offer opportunity for a detailed
analysis of intra and intercellular signaling-related to motor
neuron toxicity.
The profiling of gene expression using different platforms
have been largely employed in the ALS model in several stages
of the disease course (Olsen et al., 2001; Dangond et al., 2004;
Malaspina and De Belleroche, 2004; Jiang et al., 2005; Perrin
et al., 2005; Ferraiuolo et al., 2007, 2011a; Yamamoto et al.,
2007; Offen et al., 2009; Brockington et al., 2010; D’arrigo
et al., 2010; Guipponi et al., 2010; Saris et al., 2013b; Yu
et al., 2013), including the early symptomatic phase (Olsen
et al., 2001; Yoshihara et al., 2002; Ferraiuolo et al., 2007; Yu
et al., 2013), however, there is a lack of information on dif-
ferential gene expression taking place before classical clinical
symptoms (Olsen et al., 2001; Yoshihara et al., 2002; Ferraiuolo
et al., 2007; Guipponi et al., 2010). Olsen et al. (2001) inau-
gurated that issue by looking at patterns of gene expression
from SOD1G93A spinal cord by means of a murine restricted
platform of oligonucleotide microarray and by describing neg-
ligible changes in the transcript profile at the pre-symptomatic
phases. Other authors that have examined gene profiling in pre-
symptomatic phases of ALS disease employed restricted platforms
of cDNA arrays, used animals with an uncommon symptom
onset (Yoshihara et al., 2002; Guipponi et al., 2010) or eval-
uated gene profiling in specific spinal cord cells (Ferraiuolo
et al., 2007, 2011a). Authors have encountered gene expres-
sions related to inflammation, apoptosis, oxidative stress, ATP
biosynthesis, myelination, axonal transport as candidates of bio-
logical processes taking place in the pre-symptomatic periods
of ALS.
By means of a high-density oligonucleotide microarrays linked
to specific tools capable to identify enriched pathways, the aim
of this work was to identify early molecular changes in the pre-
symptomatic stage in the spinal cord of the SOD1G93A mouse
model. The data showed important alterations at early 40 days
pre-symptomatic period of disease and in 80 days old pre-
symptomatic mice.
MATERIALS AND METHODS
SAMPLES
Specific pathogen-free male SOD1G93A mice of preclinical 40
and 80 days old mice and their age-paired non-transgenic wild-
type controls, 20–25 g body weight, from University of São Paulo
Medical School (São Paulo, Brazil) were used in the experiments.
A total of 5 animals were used in each group in microarray
experiments, while in the verification experiments by quantita-
tive polymerase chain reaction (qPCR) and laser microdissection,
each group was comprised for 6 and 3 different animals, respec-
tively. Animals were kept under standardized lighting conditions
(lights on at 7:00 h and off at 19:00 h), at a constant temperature
of 23◦C and with free access to food pellets and tap water. The
colony was derived from Jackson Laboratories (Bar Harbor, ME,
USA) fromG93Amutant mice with 25 ± 1.5 copies of the human
SOD1 transgene (Gurney, 1994). Mouse identification (SODG93A
or WT) in our colony was performed by genotyping (Scorisa
et al., 2010). Animals were killed by decapitation and their lum-
bar spinal cords were collected for molecular analysis. The study
was conducted according protocols approved by the Animal Care
and Use of Ethic Committee at the University of São Paulo and
in accordance with the Guide for Care and Use of Laboratory
Animals adopted by the National Institutes of Health.
RNA EXTRACTION
Total RNA was isolated using the MiniSpin kit for RNA
extraction (GE Healthcare, USA) according to the manufac-
turer’s instructions. RNA quantity and integrity were assessed
by spectrophotometry (Nanodrop, Thermo Scientific, USA) and
microfluidics—based electrophoresis (Agilent 2100 Bioanalyzer,
Agilent Technologies, USA), respectively. RNA samples with OD
260/280 of approximately 2.0 and RIN > 7.0 were used for
microarray experiments and qPCR. A pool of RNAs from neona-
tal organs (heart, kidney, liver) was employed as reference sample.
A representative eletropherogram from Bioanalyzer evaluation of
RNA integrity is shown in supplementary material (Figure S1).
MICROARRAY EXPERIMENTS
For samples and reference, respectively, 250 and 500 ng of
RNA were reverse transcribed by the Low-input RNA Linear
Amplification Kit (Agilent Technologies) and then transcribed
to Cy3-labeled (samples) or Cy5-labeled (reference) cRNA
according to the manufacturer. The labeled cRNA was purified
(Minispin kit, GE Life Sciences), and the dye content and con-
centration of cRNA were measured by a NanoDrop ND-1000
spectrophotometer (Thermo Scientific). A total of 850 ng of Cy3-
labeled cRNA was hybridized together with the same amount
of Cy5-labeled reference to Whole Mouse Genome Oligo 4 ×
44K microarrays overnight at 65◦C, and then the slides were
washed and treated with Stabilizing and Drying Solution (Agilent
Technologies) and scanned by Agilent Microarray Scanner. All
steps were performed according to the manufacturer (Agilent
Technologies).
The raw data from hybridizations and experimental conditions
are available on the Gene Expression Omnibus website under
accession number GSE50642.
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DATA ANALYSES
The Feature Extraction Software v9.1.3.1 (Agilent Technologies)
was used to extract and analyze the assay signals and subsequently
determine the signal-to-noise ratios from the microarray images.
Microarrays without enough quality were taken out from fur-
ther analysis. The analysis proceeded with 4 samples for each
group. Microarray raw data (.txt files) were imported into R v.
3.0.1 (Team RDC, 2012) and analyzed with the Bioconductor
(Gentleman et al., 2004) packages Agi4×44PreProcess and limma
(Smyth, 2005). Briefly, after quality check, the microarray probes
were filtered and their median foreground intensity was normal-
ized within and between arrays according to Agi4×44Preprocess
and limma user guides, respectively. Finally, the probes were
tested for differential expression using a linear model followed
by Bayes moderated t-test (Smyth, 2005) for the compar-
isons of interest. Genes with nominal p < 0.05 were accepted
to be differentially expressed and further considered in the
analysis.
FunNet ANALYSIS
In order to further identify over-represented pathways and bio-
logical process, the lists with differentially expressed genes for
both 40 and 80 days old mice were split into lists of up and
down regulated genes and submitted to FunNet web based
tool (Functional Analysis of Transcriptional Networks), using
Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene
Ontology (GO) annotations (Prifti et al., 2008).
LASER MICRODISSECTION OF ASTROCYTES
The lumbar spinal cord of mice were rapidly removed and
immediately frozen in ice cold isopentane at −45◦C and stored
at −80◦C until use. The labeling procedure was performed as
described previously (De Oliveira et al., 2009) and modified
according to our experience. Frozen sections (5µm) were rapidly
defrosted for 30 s and fixed with ice cold acetone, for 3min.
Sections were then incubated during 3min in phosphate buffered
saline (PBS) containing 3% Triton X-100 and then incubated
with primary antibody, a polyclonal rabbit anti-glial fibrillary
acidic protein (GFAP; Dako Cytomation; 1:100) diluted in 0.3%
Triton X-100 containing 1% BSA for 5min. Sections were then
washed in PBS for 3 times of 15 s and then incubated with texas
red-conjugated goat-anti-rabbit secondary antibody, in the same
diluent than primary antibody, in a final concentration of 1:50
during 5min in the dark and at room temperature. Sections were
rinsed carefully three times with PBS for 15 s and immediately
submitted to laser microdissection.
Around 200 astrocytes were isolated from each 40 and 80
days old mice lumbar spinal cords using P.A.L.M. Microlaser
Technologies (Zeiss). RNA was extracted using PicoPure RNA
isolation kit (Arcturus) and linear amplification of RNA was
performed following Eberwine’s procedure (Van Gelder et al.,
1990) using the RiboampHSplus kit (Arcturus) according to
the manufacturer’s protocol. The quantity (NanoDrop 1000
Spectrophotometer) and quality (Agilent 2100 bioanalyser, RNA
6000 Pico LabChip) of amplified RNA was analyzed as described
above. Also, the astrocytes enriched samples were submitted to
PCRs in order to access contamination from other cell types.
Protocol and results of astrocyte samples enrichment are pre-
sented in the supplementary material (Figure S2).
QUANTITATIVE PCR
A proportion of genes identified as differentially expressed were
selected for verification by qPCR, on the basis of robust microar-
ray data confirming differential gene expression. The genes were
chosen for verification based on their possible involvement in
ALS related mechanisms. Verification addresses the possibility
of false positive microarray signals, due to cross-hybridization
with related genes, concern about the accuracy of array probe
sets, and uncertainty about the hybridization kinetics of multi-
ple reactions occurring on the miniature scale of an array chip.
The qPCR verification of microarray results were performed on
independent sample, as described above. cDNA was synthesized
from 1µg of total RNA treated with DNAse by a reverse transcrip-
tion reagent kit (Applied Biosystems Life Technologies) according
to manufacturer. qPCR reactions were carried out in duplicate
with 40 ng cDNA, the DyNAmo ColorFlash SYBR Green qPCR
kit (Thermo Scientific, USA) and 400 nM of each primer in a final
volume reaction of 20µl, by using the PikoReal Real-Time PCR
System (Thermo Scientific). The information for SYBR primers
can be found in Table 1. For astrocytes enriched samples, 1µg
of amplified RNA was reverse transcribed to cDNA by a reverse
transcription reagent kit (Applied Biosystems Life Technologies)
modified from original protocol in order to improve efficiency.
Briefly, Oligo(dT)16 primer was added to samples and incubated
at 70◦C during 5min, then the other required reagents, such as
reaction buffer, MgCl2, dNTPs, RNAse inhibitor, in the same con-
centrations than manufacturer protocol, and 156,25 U of Reverse
transcriptase (Multiscribe), were added to reaction and incubated
at 37◦C for 60min followed by 95◦C for 5min. qPCR reactions
were carried out in duplicate using Taqman master mix and the
Table 1 | Information for primers used in SYBR qPCR experiments of
40 and 80 days old pre-symptomatic SOD1G93A and wild-type mice.
Gene ID Primer sequences (5′-3′) Amplicon (bp)
Glg1 F: GAGTGAGATTGCAGCCAGAG 143
R:CAGGATGTAGTTCTTTGAGGGAG
Aqp4 F: GCTCGATCTTTTGGACCCG 112
R: AGACATACTCATAAAGGGCACC
Calca F: TGCAGATGAAAGCCAGGG 149
R: CTTCACCACACCTCCTGATC
Eef2 F: CATGTTTGTGGTCAAGGCATAC 141
R:TTGTCAAAAGGATCCCCAGG
Nsg1 F: AAGTGTACAAGTATGACCGCG 128
R: GACAGTGTAAAATTTCTCCCGG
Syt10 F: AGACCATTGGAACGAGATGC 148
R: TGGAGGCTTTTATGGTGTGG
NORMALYZER
Gapdh F: GAGTAAGAAACCCTGGACCAC 109
R: TCTGGGATGGAAATTGTGAGG
The Glg1, Aqp4, Calca genes and Eef2, Nsg1, Syt10 genes were verified in 40
and 80 days mice, respectively, according to microarray results.
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following assays were used: Ube2i (Mm04243971_g1) and Gapdh
(Mm99999915_g1).
For SYBR reactions the cycling was composed by an initial
denaturation at 95◦C for 10min, templates were amplified by
40 cycles of 95◦C for 15 s and 60◦C for 30 s. A dissociation
curve was then generated to ensure amplification of a single
product, and absence of primer dimers. For each primer pair, a
standard curve was generated to determine the efficiency of the
PCR reaction over a range of template concentrations from 0.032
ng/µl to 20 ng/µl, using cDNA synthesized from mouse refer-
ence RNA. The efficiency for each set of primers was 100 ± 5%.
For Taqman reactions, cycling was composed by an initial step
of 50◦C for 2min, followed by denaturation at 95◦C for 10min,
templates were amplified by 40 cycles of 95◦C for 15 s and 60◦C
for 1min. Gene expressions, normalized to Gapdh, could be
determined using the Ct mathematical model (ABI PRISM
7700 Sequence Detection System protocol; Applied Biosystems).
One-tailed unpaired t-test was used to determine the statistical
significance of any differences in gene expression [GraphPad (San
Diego, CA) Prism 5]. Gapdh was chosen as a housekeeping gene
to normalize the qPCR values because the microarray analysis
showed that its expression was stable across samples.
RESULTS
GENERAL FEATURES OF DIFFERENTIAL GENE EXPRESSION BETWEEN
SOD1G93A ANDWILD-TYPE MICE
Statistical analysis has pointed to 492 differentially expressed
genes at the lumbar region of 40 days SOD1G93A, compared to
the age matched wild-type mice, being 155 up and 337 down reg-
ulated genes, respectively, while 1105 genes were found differen-
tially expressed by 80 days old ALSmice compared to agematched
controls, being 433 up and 672 down regulated genes, respectively.
The whole list with differentially expressed gene for both age mice
can be found in Tables S1 and S2 in the Supplementary material.
Of interest, among differentially expressed genes, 66 are common
to both ages; they are presented in the Table 2.
VERIFICATION OF MICROARRAY RESULTS BY qPCR
The results of qPCR verification for the six representative genes
are shown in Table S3 (Supplementary material). The up and
down regulations of the verified genes in the 40 days and 80
days old SOD1G93A mice by means of qPCR were coincident and
supported the microarray findings of correspondent animal ages
(Table S3).
FunNet ANALYSIS
KEGG terms which were significantly enriched (at level p < 0.05)
amongst differentially expressed genes between SOD1G93A and
wild-type mice were identified for both 40 days and 80 days old
pre-symptomatic ALS mice. Over-represented KEGG pathways
and respective genes taking part of them are given in Tables 3, 4.
Of importance, differentially expressed genes from 40 and 80 days
old mice allowed to recognize 7 pathways common among both
periods (Figure 1). Those were glutamatergic synapse, ubiquitin
mediated proteolysis, chemokine signaling pathway, endocytosis,
oxidative phosphorylation, antigen processing and presentation
and tight junction. The number of transcripts in each pathway
Table 2 | Differentially expressed genes common to both gene lists of
40 and 80 days old pre-symptomatic SOD1G93A and wild-type mice.
Gene symbol Fold change 40 days Fold change 80 days
Ocel1 −1.68 −1.92
Fam32a −1.45 −1.61
Trim37 1.22 −1.34
Lsm6 −1.3 −1.29
Map1a 1.2 −1.15 and −1.28
Bmpr2 1.21 −1.26
Eif3j2 1.29 −1.26
Foxn3 1.28 −1.25
Plekha5 1.17 −1.25
Rfxank −1.12 −1.22
Malat1 1.1 −1.21
Ddx6 1.3 −1.19
Huwe1 1.12 −1.19
Snx27 1.19 −1.19
Srrm3 1.18 −1.19
Dzip1 1.14 −1.17
Hook3 1.14 −1.17
Nemf 1.15 −1.16
Pdlim5 1.09 −1.16
Plvap −1.14 −1.16
Thrap3 1.15 −1.16
Srsf11 −1.1 −1.15
Azin1 1.12 −1.14
Eif5b 1.19 −1.14
Hspa4 1.1 −1.14
Kras 1.19 −1.14
Sp4 1.12 −1.14
Tusc3 −1.1 −1.14
Vegfa 1.12 −1.14
Fam133b 1.09 −1.13
Fam81a 1.12 −1.13
Prkrir −1.1 −1.13
Ptrf −1.3 −1.13
6330411E07Rik 1.09 −1.12
Gria4 1.18 −1.12
Zfp866 1.07 −1.12
Marc-2 −1.07 −1.11
Hadh 1.12 −1.11
Mtf2 1.1 −1.11
Dhps −1.09 −1.1
Nsd1 1.12 −1.1
Mier1 1.13 −1.09
U2surp 1.13 −1.09
2610507B11Rik 1.07 1.1
Ncam1 1.17 1.12
Rtn1 −1.17 1.12
Chd5 1.12 1.13
Dhcr7 −1.08 1.15
Strbp 1.15 1.15
Synm −1.12 1.15
Map7d1 1.14 1.16
Specc1 1.1 1.17
(Continued)
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Table 2 | Continued
Gene symbol Fold change 40 days Fold change 80 days
Maea 1.1 1.19
Ncl 1.1 and −1.1 1.19
Glg1 1.29 1.2
Dnajc27 1.17 1.21
Ncdn 1.14 1.21
Lpcat2 1.16 1.22
D17Wsu92e 1.11 1.24
Nisch 1.08 1.24
Tkt −1.1 1.25
Tmem59l 1.29 1.26
Mast3 1.24 1.28
Plac9a −1.45 1.35
Nsg1 −1.17 1.22 and 1.35
Trappc3 −1.2 1.32 and 1.41
Map1a, Ncl, Nsg1, and Trappc3 genes were represented by an additional probe.
is also shown in Figure 1. Moreover, other interesting pathways
could also be identified to appear only in 40 days (Table 3)
or 80 days old SOD1G93A mice (Table 4). Furthermore, among
pathways common to both ages, ubiquitin mediated proteoly-
sis, chemokine signaling pathway and endocytosis were over-
represented by up regulated genes and oxidative phosphorylation
was pointed by down regulated genes (Figure 1). Furthermore,
glutamatergic synapse and tight junction were pointed by the
genes that were up regulated in 40 days and also up or down
regulated in 80 days gene expression lists (Figure 1). Finally,
antigen processing and presentation was pointed for down reg-
ulated genes in 40 days and up regulated genes in 80 days lists
(Figure 1).
Some pathways pointed by FunNet were omitted from table
because they were composed by genes already presented in other
pathways and also genes apparently not related to ALS. They
were melanoma, measles, hepatitis C, melanogenesis, pathways in
cancer and prostate cancer at 40 days and viral myocarditis and
melanogenesis in 80 days results.
The results for GO enriched terms can be found in Tables S4
and S5 in Supplementary material.
LASER MICRODISSECTION OF ASTROCYTES AND qPCR EXPERIMENT
The profile for GFAP immunofluorescence for specific identi-
fication of astrocytes can be found in Figure 2. Our protocol
allowed easily identifying the astrocytic profiles (Figure 2A) to
be microdissected (Figure 2B). The procedure allowed a com-
plete microdissection of the desired cell type (Figure 2C), the
astrocytes in our case. The results of qPCR for Ube2i, using
the two cycle amplified RNA, from 40 and 80 days mouse laser
microdissected astrocytes have shown increased gene expressions
in transgenic mice of both pre-symptomatic ages (Figure 3). The
Ube2i expression was increased by 5.53-fold in the astrocytes from
40 days old SOD1G92A mice and by 1.77-fold change in astro-
cytes from 80 days old SOD1G92A mice compared to respective
age matched wild-type samples.
Table 3 | KEGG pathways enriched amongst differentially expressed
up or down regulated genes at 40 days old mice.
Gene ID Gene symbol Gene name
PATHWAYS POINTED BY UP REGULATED GENES
Fructose and manose metabolism
170768 Pfkfb3 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3
18640 Pfkfb2 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2
18642 Pfkm Phosphofructokinase, muscle
230163 Aldob Aldolase B, fructose-bisphosphate
54384 Mtmr7 Myotubularin related protein 7
Tight junction
14677 Gnai1 Guanine nucleotide binding protein (G protein),
alpha inhibiting 1
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
18176 Nras Neuroblastoma ras oncogene
18417 Cldn11 Claudin 11
192195 Ash1l Ash1 (absent, small, or homeotic)-like
(Drosophila)
Glutamatergic synapse
140919 Slc17a6 Solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 6
14677 Gnai1 Guanine nucleotide binding protein (G protein),
alpha inhibiting 1
14802 Gria4 Glutamate receptor, ionotropic, AMPA4 (alpha 4)
14810 Grin1 Glutamate receptor, ionotropic, NMDA1 (zeta 1)
20511 Slc1a2 Solute carrier family 1 (glial high affinity
glutamate transporter), member 2
Axon guidance
12767 Cxcr4 Chemokine (C-X-C motif) receptor 4
14677 Gnai1 Guanine nucleotide binding protein (G protein),
alpha inhibiting 1
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
18176 Nras Neuroblastoma ras oncogene
22253 Unc5c Unc-5 homolog C (C. elegans)
56637 Gsk3b Glycogen synthase kinase 3 beta
Ubiquitin mediated proteolysis
107568 Wwp1 WW domain containing E3 ubiquitin protein
ligase 1
17999 Nedd4 Neural precursor cell expressed,
developmentally down-regulated 4
22210 Ube2b Ubiquitin-conjugating enzyme E2B
59026 Huwe1 HECT, UBA and WWE domain containing 1
68729 Trim37 Tripartite motif-containing 37
70790 Ubr5 Ubiquitin protein ligase E3 component
n-recognin 5
Chemokine signaling pathway
12767 Cxcr4 Chemokine (C-X-C motif) receptor 4
14677 Gnai1 Guanine nucleotide binding protein (G protein),
alpha inhibiting 1
(Continued)
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Table 3 | Continued
Gene ID Gene symbol Gene name
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
18176 Nras Neuroblastoma ras oncogene
18708 Pik3r1 Phosphatidylinositol 3-kinase, regulatory
subunit, polypeptide 1 (p85 alpha)
56637 Gsk3b Glycogen synthase kinase 3 beta
73178 Wasl Wiskott-Aldrich syndrome-like (human)
Endocytosis
107568 Wwp1 WW domain containing E3 ubiquitin protein
ligase 1
12767 Cxcr4 Chemokine (C-X-C motif) receptor 4
13854 Epn1 Epsin 1
17999 Nedd4 Neural precursor cell expressed,
developmentally down-regulated 4
193740 Hspa1a Heat shock protein 1A
26431 Git2 G protein-coupled receptor kinase-interactor 2
78618 Acap2 ArfGAP with coiled-coil, ankyrin repeat and PH
domains 2
PATHWAYS POINTED BY DOWN REGULATED GENES
Nucleotide excision repair
19718 Rfc2 Replication factor C (activator 1) 2
66979 Pole4 Polymerase (DNA-directed), epsilon 4 (p12
subunit)
DNA replication
19718 Rfc2 Replication factor C (activator 1) 2
66979 Pole4 Polymerase (DNA-directed), epsilon 4 (p12
subunit)
Fatty acid metabolism
11363 Acadl Acyl-Coenzyme A dehydrogenase, long-chain
74205 Acsl3 Acyl-CoA synthetase long-chain family member
3
TGF-beta signaling pathway
12167 Bmpr1b Bmpr1b bone morphogenetic protein receptor,
type 1B
15902 Id2 Inhibitor of DNA binding 2
19651 Rbl2 Retinoblastoma-like 2
Antigen processing and presentation
12010 B2m Beta-2 microglobulin
12317 Calr Calreticulin
19727 Rfxank Regulatory factor X-associated
ankyrin-containing protein
ECM-receptor interaction
11603 Agrn Agrin
12814 Col11a1 Collagen, type XI, alpha 1
16773 Lama2 Laminin, alpha 2
GnRH signaling pathway
12314 Calm2 Calmodulin 2
16440 Itpr3 Inositol 1,4,5-triphosphate receptor 3
16476 Jun Jun oncogene
17390 Mmp2 Matrix metallopeptidase 2
(Continued)
Table 3 | Continued
Gene ID Gene symbol Gene name
Parkinson’s disease
104130 Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 11
12857 Cox4i1 Cytochrome c oxidase subunit IV isoform 1
66576 Uqcrh Ubiquinol-cytochrome c reductase hinge protein
67264 Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 8
Oxidative phosphorylation
104130 Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 11
12857 Cox4i1 Cytochrome c oxidase subunit IV isoform 1
66576 Uqcrh Ubiquinol-cytochrome c reductase hinge protein
67264 Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 8
Alzheimer’s disease
104130 Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 11
12314 Calm2 Calmodulin 2
12857 Cox4i1 Cytochrome c oxidase subunit IV isoform 1
16440 Itpr3 Inositol 1,4,5-triphosphate receptor 3
66576 Uqcrh Ubiquinol-cytochrome c reductase hinge protein
67264 Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 8
DISCUSSION
Gene-expression profiling studies have been conducted in the
search of molecular pathways related to motor neuron death in
ALS by employing animal models in different phases of the dis-
ease and human post mortem material at the very end stage of
motor neuron degeneration (Olsen et al., 2001; Dangond et al.,
2004;Malaspina andDe Belleroche, 2004; Jiang et al., 2005; Perrin
et al., 2005; Ferraiuolo et al., 2007, 2011a; Yamamoto et al., 2007;
Offen et al., 2009; Brockington et al., 2010; D’arrigo et al., 2010;
Guipponi et al., 2010; Saris et al., 2013b).
The analysis of the mechanisms that trigger motor neuron
death in the ALS may include evaluation of the altered molecu-
lar pathways that are taking place in compromised regions before
the occurrence of cell death. Previous works have attempted to
describe gene profiling in the pre-symptomatic phases of ALS
animal model by employing distinct methodologies (Ferraiuolo
et al., 2007; D’arrigo et al., 2010; Guipponi et al., 2010). This
is the first work to analyze gene expression profile in the whole
lumbar spinal cord of early 40 and 80 days old pre-symptomatic
SOD1G93A mouse in a whole genome array platform, which
allowed depicting enriched pathways related to possible mech-
anisms of neuronal toxicity in ALS. Our analysis has pointed
to up to 1105 differentially expressed genes in pre-symptomatic
periods of SOD1G93A mouse model, a larger number of than
described elsewhere (Perrin et al., 2005, 2006). It should be
pointed that the average of fold change described in previous
publications is about 3, which is higher than that found in
our microarray analysis. However, it must be emphasized that
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Table 4 | KEGG pathways enriched amongst differentially expressed
up or down regulated genes at 80 days old mice.
Gene ID Gene symbol Gene name
PATHWAYS POINTED BY UP REGULATED GENES
Vascular smooth muscle contraction
104111 Adcy3 Adenylate cyclase 3
12315 Calm3 Calmodulin 3
14673 Gna12 Guanine nucleotide binding protein, alpha 12
14674 Gna13 Guanine nucleotide binding protein, alpha 13
18751 Prkcb Protein kinase C, beta
213498 Arhgef11 Rho guanine nucleotide exchange factor (GEF)
11
224129 Adcy5 Adenylate cyclase 5
26413 Mapk1 Mitogen-activated protein kinase 1
Antigen processing and presentation
14963 H2-Bl Histocompatibility 2, blastocyst
14972 H2-K1 Histocompatibility 2, K1, K region
15006 H2-Q1 Histocompatibility 2, Q region locus 1
15007 H2-Q10 Histocompatibility 2, Q region locus 10
15013 H2-Q2 Histocompatibility 2, Q region locus 2
15018 H2-Q7 Histocompatibility 2, Q region locus 7
15039 H2-T22 Histocompatibility 2, T region locus 22
15040 H2-T23 Histocompatibility 2, T region locus 23
15481 Hspa8 Heat shock protein 8
21355 Tap2 Transporter 2, ATP-binding cassette, sub-family
B (MDR/TAP)
Tight junction
11465 Actg1 Actin, gamma, cytoplasmic 1
13043 Cttn Cortactin
13821 Epb4.1l1 Erythrocyte protein band 4.1-like 1
13822 Epb4.1l2 Erythrocyte protein band 4.1-like 2
14924 Magi1 Membrane associated guanylate kinase, WW
and PDZ domain containing 1
16897 Llgl1 Lethal giant larvae homolog 1
17475 Mpdz Multiple PDZ domain protein
18751 Prkcb Protein kinase C, beta
67374 Jam2 Junction adhesion molecule 2
71960 Myh14 Myosin, heavy polypeptide 14
Chemokine signaling pathway
104111 Adcy3 Adenylate cyclase 3
14083 Ptk2 PTK2 protein tyrosine kinase 2
14688 Gnb1 Guanine nucleotide binding protein (G protein),
beta 1
14693 Gnb2 Guanine nucleotide binding protein (G protein),
beta 2
14697 Gnb5 Guanine nucleotide binding protein (G protein),
beta 5
14701 Gng12 Guanine nucleotide binding protein (G protein),
gamma 12
14708 Gng7 Guanine nucleotide binding protein (G protein),
gamma 7
18751 Prkcb Protein kinase C, beta
(Continued)
Table 4 | Continued
Gene ID Gene symbol Gene name
224129 Adcy5 Adenylate cyclase 5
26413 Mapk1 Mitogen-activated protein kinase 1
277360 Prex1 Phosphatidylinositol-3,4,5-trisphosphate-
dependent Rac exchange
factor 1
Ubiquitin mediated proteolysis
103583 Fbxw11 F-box and WD-40 domain protein 11
15204 Herc2 Hect (homologous to the E6-AP (UBE3A)
carboxyl terminus) domain and RCC1
(CHC1)-like domain (RLD) 2
17237 Mgrn1 Mahogunin, ring finger 1
19823 Rnf7 Ring finger protein 7
217342 Ube2o Ubiquitin-conjugating enzyme E2O
22192 Ube2m Ubiquitin-conjugating enzyme E2M
22196 Ube2i Ubiquitin-conjugating enzyme E2I
22213 Ube2g2 Ubiquitin-conjugating enzyme E2G 2
229615 Pias3 Protein inhibitor of activated STAT 3
50754 Fbxw7 F-box and WD-40 domain protein 7
63958 Ube4b Ubiquitination factor E4B, UFD2 homolog (S.
cerevisiae)
Regulation of actin cytoskeleton
11465 Actg1 Actin, gamma, cytoplasmic 1
14083 Ptk2 PTK2 protein tyrosine kinase 2
14673 Gna12 Guanine nucleotide binding protein, alpha 12
14674 Gna13 Guanine nucleotide binding protein, alpha 13
14701 Gng12 Guanine nucleotide binding protein (G protein),
gamma 12
18717 Pip5k1c Phosphatidylinositol-4-phosphate 5-kinase, type
1 gamma
192897 Itgb4 Integrin beta 4
226970 Arhgef4 Rho guanine nucleotide exchange factor (GEF) 4
227753 Gsn Gelsolin
26413 Mapk1 Mitogen-activated protein kinase 1
67771 Arpc5 Actin related protein 2/3 complex, subunit 5
71960 Myh14 Myosin, heavy polypeptide 14
Glutamatergic synapse
104111 Adcy3 Adenylate cyclase 3
110637 Grik4 Glutamate receptor, ionotropic, kainate 4
14645 Glul Glutamate-ammonia ligase (glutamine
synthetase)
14688 Gnb1 Guanine nucleotide binding protein (G protein),
beta 1
14693 Gnb2 Guanine nucleotide binding protein (G protein),
beta 2
14697 Gnb5 Guanine nucleotide binding protein (G protein),
beta 5
14701 Gng12 Guanine nucleotide binding protein (G protein),
gamma 12
14708 Gng7 Guanine nucleotide binding protein (G protein),
gamma 7
18751 Prkcb Protein kinase C, beta
216456 Gls2 Glutaminase 2 (liver, mitochondrial)
224129 Adcy5 Adenylate cyclase 5
26413 Mapk1 Mitogen-activated protein kinase 1
(Continued)
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Table 4 | Continued
Gene ID Gene symbol Gene name
Phagosome
11465 Actg1 Actin, gamma, cytoplasmic 1
14963 H2-Bl Histocompatibility 2, blastocyst
14972 H2-K1 Histocompatibility 2, K1, K region
15006 H2-Q1 Histocompatibility 2, Q region locus 1
15007 H2-Q10 Histocompatibility 2, Q region locus 10
15013 H2-Q2 Histocompatibility 2, Q region locus 2
15018 H2-Q7 Histocompatibility 2, Q region locus 7
15039 H2-T22 Histocompatibility 2, T region locus 22
15040 H2-T23 Histocompatibility 2, T region locus 23
15239 Hgs HGF-regulated tyrosine kinase substrate
17113 M6pr Mannose-6-phosphate receptor, cation
dependent
21355 Tap2 Transporter 2, ATP-binding cassette, sub-family
B (MDR/TAP)
22142 Tuba1a Tubulin, alpha 1A
22151 Tubb2a Tubulin, beta 2A class IIA
Protein processing in endoplasmic reticulum
100037258 Dnajc3 DnaJ (Hsp40) homolog, subfamily C, member 3
108687 Edem2 ER degradation enhancer, mannosidase
alpha-like 2
12955 Cryab Crystallin, alpha B
15481 Hspa8 Heat shock protein 8
20014 Rpn2 Ribophorin II
20338 Sel1l Sel-1 suppressor of lin-12-like (C. elegans)
216440 Os9 Amplified in osteosarcoma
22213 Ube2g2 Ubiquitin-conjugating enzyme E2G 2
269523 Vcp Valosin containing protein
50907 Preb Prolactin regulatory element binding
54197 Rnf5 Ring finger protein 5
56453 Mbtps1 Membrane-bound transcription factor peptidase,
site 1
56812 Dnajb2 DnaJ (Hsp40) homolog, subfamily B, member 2
63958 Ube4b Ubiquitination factor E4B, UFD2 homolog (S.
cerevisiae)
Cell adhesion molecules (CAMS)
14963 H2-Bl Histocompatibility 2, blastocyst
14972 H2-K1 Histocompatibility 2, K1, K region
15006 H2-Q1 Histocompatibility 2, Q region locus 1
15007 H2-Q10 Histocompatibility 2, Q region locus 10
15013 H2-Q2 Histocompatibility 2, Q region locus 2
15018 H2-Q7 Histocompatibility 2, Q region locus 7
15039 H2-T22 Histocompatibility 2, T region locus 22
15040 H2-T23 Histocompatibility 2, T region locus 23
17967 Ncam1 Neural cell adhesion molecule 1
18007 Neo1 Neogenin
19274 Ptprm Protein tyrosine phosphatase, receptor type,M
20340 Glg1 Golgi apparatus protein 1
20970 Sdc3 Syndecan 3
58235 Pvrl1 Poliovirus receptor-related 1
67374 Jam2 Junction adhesion molecule 2
(Continued)
Table 4 | Continued
Gene ID Gene symbol Gene name
Endocytosis
11771 Ap2a1 Adaptor-related protein complex 2, alpha 1
subunit
12757 Clta Clathrin, light polypeptide (Lca)
13196 Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH
domain1
13429 Dnm1 Dynamin 1
14963 H2-Bl Histocompatibility 2, blastocyst
14972 H2-K1 Histocompatibility 2, K1, K region
15006 H2-Q1 Histocompatibility 2, Q region locus 1
15007 H2-Q10 Histocompatibility 2, Q region locus 10
15013 H2-Q2 Histocompatibility 2, Q region locus 2
15018 H2-Q7 Histocompatibility 2, Q region locus 7
15039 H2-T22 Histocompatibility 2, T region locus 22
15040 H2-T23 Histocompatibility 2, T region locus 23
15239 Hgs HGF-regulated tyrosine kinase substrate
15481 Hspa8 Heat shock protein 8
16835 Ldlr Low density lipoprotein receptor
18717 Pip5k1c Phosphatidylinositol-4-phosphate 5-kinase, type
1 gamma
234852 Chmp1a Charged multivesicular body protein 1A
243621 Iqsec3 IQ motif and Sec7 domain 3
67588 Rnf41 Ring finger protein 41
98366 Smap1 Stromal membrane-associated protein 1
PATHWAYS POINTED BY DOWN REGULATED GENES
VEGF signaling pathway
11651 Akt1 Thymoma viral proto-oncogene 1
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
19056 Ppp3cb Protein phosphatase 3, catalytic subunit, beta
isoform
22339 Vegfa Vascular endothelial growth factor A
Long-term depression
14678 Gnai2 Guanine nucleotide binding protein (G protein),
alpha inhibiting 2
14683 Gnas GNAS (guanine nucleotide binding protein, alpha
stimulating) complex locus
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
18795 Plcb1 Phospholipase C, beta 1
60596 Gucy1a3 Guanylate cyclase 1, soluble, alpha 3
Gap junction
14678 Gnai2 Guanine nucleotide binding protein (G protein),
alpha inhibiting 2
14683 Gnas GNAS (guanine nucleotide binding protein, alpha
stimulating) complex locus
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
18795 Plcb1 Phospholipase C, beta 1
60596 Gucy1a3 Guanylate cyclase 1, soluble, alpha 3
(Continued)
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Table 4 | Continued
Gene ID Gene symbol Gene name
RNA degradation
104625 Cnot6 CCR4-NOT transcription complex, subunit 6
13209 Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6
66373 Lsm5 LSM5 homolog, U6 small nuclear RNA
associated (S. cerevisiae)
72662 Dis3 DIS3 mitotic control homolog (S. cerevisiae)
78651 Lsm6 LSM6 homolog, U6 small nuclear RNA
associated (S. cerevisiae)
Parkinson’s disease
12866 Cox7a2 Cytochrome c oxidase subunit VIIa 2
333182 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2
66142 Cox7b Cytochrome c oxidase subunit VIIb
66495 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 3
66916 Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 7
68202 Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
Oxidative phosphorylation
12866 Cox7a2 Cytochrome c oxidase subunit VIIa 2
333182 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2
66142 Cox7b Cytochrome c oxidase subunit VIIb
66495 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 3
66916 Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 7
68202 Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
Tight junction
11651 Akt1 Thymoma viral proto-oncogene 1
14678 Gnai2 Guanine nucleotide binding protein (G protein),
alpha inhibiting 2
16653 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog
17888 Myh6 Myosin, heavy polypeptide 6, cardiac muscle,
alpha
30960 Vapa Vesicle-associated membrane protein,
associated protein A
58187 Cldn10 Claudin 10
Glutamatergic synapse
14678 Gnai2 Guanine nucleotide binding protein (G protein),
alpha inhibiting 2
14683 Gnas GNAS (guanine nucleotide binding protein, alpha
stimulating) complex locus
14702 Gng2 Guanine nucleotide binding protein (G protein),
gamma 2
14802 Gria4 Glutamate receptor, ionotropic, AMPA4 (alpha 4)
14805 Grik1 Glutamate receptor, ionotropic, kainate 1
18795 Plcb1 Phospholipase C, beta 1
19056 Ppp3cb Protein phosphatase 3, catalytic subunit, beta
isoform
216227 Slc17a8 Solute carrier family 17 (sodium-dependent
inorganic phosphate cotransporter), member 8
(Continued)
Table 4 | Continued
Gene ID Gene symbol Gene name
Huntington’s disease
12866 Cox7a2 Cytochrome c oxidase subunit VIIa 2
18795 Plcb1 Phospholipase C, beta 1
333182 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2
66142 Cox7b Cytochrome c oxidase subunit VIIb
66495 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 3
66916 Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 7
68202 Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
69920 Polr2i Polymerase (RNA) II (DNA directed)
polypeptide I
Alzheimer’s disease
11820 App Amyloid beta (A4) precursor protein
12866 Cox7a2 Cytochrome c oxidase subunit VIIa 2
18795 Plcb1 Phospholipase C, beta 1
19056 Ppp3cb Protein phosphatase 3, catalytic subunit, beta
isoform
333182 Cox6b2 Cytochrome c oxidase subunit VIb polypeptide 2
66142 Cox7b Cytochrome c oxidase subunit VIIb
66495 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 3
66916 Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 7
68202 Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 5
Ribosome
19951 Rpl32 Ribosomal protein L32
19981 Rpl37a Ribosomal protein L37a
19982 Rpl36a Ribosomal protein L36A
20068 Rps17 Ribosomal protein S17
20085 Rps19 Ribosomal protein S19
22186 Uba52 Ubiquitin A-52 residue ribosomal protein fusion
product 1
57294 Rps27 Ribosomal protein S27
66489 Rpl35 Ribosomal protein L35
67945 Rpl41 Ribosomal protein L41
68028 Rpl22l1 Ribosomal protein L22 like 1
75617 Rps25 Ribosomal protein S25
subtle changes in gene expression are exactly those that occur
in initial stages of disease before the onset of clinical symp-
toms (Druyan et al., 2008). Moreover, some authors have argued
that even small differences can be biologically relevant (Pedotti
et al., 2008). Indeed, our qPCR verification analysis revealed
higher fold changes than in the microarray, reaching values
higher than 2 in the 80 days pre-symptomatic phase, which
is closer to the symptom onset. The use of qPCR analysis to
qualitatively verify the microarray results is largely accepted in the
literature. However, it is well recognized that both methods
have quantitative differences (Chuaqui et al., 2002), which are
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FIGURE 1 | KEGG pathways classification showing the number of
transcripts up regulated and down regulated per category in 40 and 80
days pre-symptomatic SOD1G93Amice in relation to age matched
wild-types. Bars on the left indicate the number of down regulated genes,
and bars on the right indicate the number of up regulated genes, for each
category.
thought to be related to the variation in the hybridization kinet-
ics of the technologies, low fold changes or lack of concordance
between transcripts accessed in each method. The number of
genes employed in qPCR validation is comparable to that found
by other studies (Dallas et al., 2005; Brockington et al., 2010).
The differentially expressed genes with a p-value lower than
0.05 were submitted to enrichment analyses based on GO and
KEGG databases, which correlated genes to already described
related pathways and processes. Modulated genes based on GO
evidenced more general biological processes that might be impli-
cated in the ALS mechanisms. Of interest, regulation of astro-
cyte differentiation, protein retention in endoplasmatic reticulum
lumen, Golgi vesicle transport and fructose metabolism, among
others, were pointed at the pre-symptomatic 40 days old trans-
genic mice. At later pre-symptomatic phase of 80 days, the pattern
of gene expression identified the GO terms post-Golgi vesicle-
mediated transport, tricarboxylic acid cycle (TCA) and mRNA
processing, among others. GO database analyses have been largely
employed in the ALS research in several phases of the disease
(Ferraiuolo et al., 2007, 2011a; Brockington et al., 2010).
Authors have also used the KEGG database to identify over-
represented pathways based on differentially expressed genes
obtained by the microarray technique (Mougeot et al., 2011;
Kalathur et al., 2012). The KEGG database analysis in the present
work pointed to pathways that might be related to ALS mech-
anism at the pre-symptomatic ages of SOD1G93A mice. Some
pathways were found to be common to both pre-symptomatic
periods, emphasizing the putative toxic triggering that may last
before the onset of classical ALS symptoms with possible signifi-
cance to mechanisms of initiation of motor neuron degeneration.
Those pathways are going to be discussed below. It should be
mentioned that alternative splicing have been recently impli-
cated in ALS mechanisms (Lenzken et al., 2011; Singh and
Cooper, 2012), however we could not access this biological event
because the present analysis employed a platform designed to
gene expression studies on 3′UTR that does not allow evaluation
of alternative splicing variants.
GLUTAMATERGIC SYNAPSE
The microarray profiling study by means of KEEG enriched anal-
ysis pointed to the category of glutamatergic synapse pathway in
the lumbar spinal cord of ALS SOD1G93A. The large number of
up regulated genes at 40 and 80 days underlines the excitotoxicity
estate mediated by glutamatergic synapse of motor neurons in the
pre-symptomatic condition of ALS disease (Bendotti et al., 2001;
Gibb et al., 2007; Zhao et al., 2008; Jiang et al., 2009; Sunico et al.,
2011). The modulation of GluR4, by means of Gria4 findings in
our microarray analysis, might reflect the dynamic state of the
AMPA receptor subunit in the course of pre-symptomatic stages
of ALS. At the early phases of the pre-symptomatic period, highly
expressed Gria4 gene might contribute to the AMPA receptor-
mediated motor neuron toxicity, being a very early mechanism
of the disease. The down regulation of the Gria4 at the late pre-
symptomatic stage could reflect a transient reactive mechanism to
excitotoxic condition preceding motor neuron death. Reductions
of GluR4 have been described at cellular level in the late disease
stage of SOD1 mice, without alterations at the pre-symptomatic
periods (Petri et al., 2005) thus, reflecting a disappearance of
GluR4 containing neurons. In fact, imbalance of excitatory to
inhibitory synaptic function precedesmotor neuron degeneration
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FIGURE 2 | Photomicrographs illustrating astrocyte laser
microdissection process. (A) The quick GFAP immunofluorescence allows
recognizing the astrocytic profiles (arrows). (B) Astrocytes (1 and 2) were
then selected for microdissection. (C) After laser firing and microdissection,
selected cells (arrows) can no longer be visualized in the tissue. Scale bars
of 20µm.
as described in the spinal cord motor neurons in the late stage
of pre-symptomatic phase of SOD1 ALS model by means of
cellular analyses (Schutz, 2005). It should be mentioned that
Ca2+ permeability of the AMPA receptor seems to occur mainly
by the presence of the GluR2 subunit in the receptor complex.
In fact, GluR2 deficiency clearly accelerated the motor neuron
degeneration and shortened the life span of mutant SOD1G93A
double transgenic mice (Tateno et al., 2004). Synaptic GluR1
increases/mRNA up regulation, and decreases of synaptic and
total GluR2 were found at early ages prior to disease onset thus
prompting motor neurons to a higher Ca2+-permeable AMPA
FIGURE 3 | Graph shows relative fold change values for Ube2i in
microdissected astrocytes from 40 and 80 days old SOD1G93A mice
compared to the age matched wild-type controls (WT). Significant
increases are seen in both transgenic astrocytes enriched samples. Results
are presented as means ± s.e.m. from 3 samples used for each group.
∗p-value < 0.05, according to unpaired t-test.
receptors -induced excitotoxicity (Zhao et al., 2008). The variant
C-terminus of GluR4 (GluR4c), an alternative splicing isoform,
stabilizes and locates AMPA receptors in the cell membrane, and
also seems to potentate actions of GluR2 (Kawahara et al., 2004),
thus highlighting the pivotal role of GluR4 subunit in regulating
channel properties and trafficking of AMPA receptors. It must be
then further clarified the role of GluR4 in the ALS mechanisms
and possible dynamic interaction with that subunit with other
AMPA receptor subtypes, especially GluR2.
The regulation of Slc1a2 glial glutamate transporter (named
EAAT2 or glial glutamate transporter GLT1) has not been eval-
uated in details. Excitotoxicity caused by a down-regulation of
EAAT2 is thought to be a contributing factor to motor neuron
death in ALS. Several mechanismsmay account for impairment of
EAAT2 function, for instance altered transcription/splicing, post-
translational modifications, accelerated degradation, intracelu-
lar trafficking and inactivation by caspase-3 cleavage (Heath
and Shaw, 2002; Boston-Howes et al., 2006) but not directly
to gene regulation processes. It is possible that the impaired
EAAT2 function could take place at the very early period of
the pre-symptomatic stage, a matter that remains to be eluci-
dated (Bendotti et al., 2001; Sasaki et al., 2001), thus, explaining
the Slc1a2 expression possibly related to motor neuron protec-
tion at those ages. The absence of this genomic process in the
late pre-symptomatic period might potentiate loss of function
of GLT1 thus culminating with the motor neuron death in ALS.
Furthermore, the vesicular glutamate transporter 2 (VGLUT2),
codified by Slc17a6 gene, was found to be regulated and related
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to neuronal death in the pre-symptomatic stage of ALS model
(Schutz, 2005; Sunico et al., 2011). The genetic reduction of
VGLUT2 protein level in the ALS mouse model accounted for
motor neuron rescue without modifying functional impairment
(Wootz et al., 2010). It is possible that the up regulation of the
Slc17a6 gene at the early pre-symptomatic stage of the 40 days old
SOD1G93A mice potentiates the toxic state of motor neurons.
UBIQUITIN MEDIATED PROTEOLYSIS AND OXIDATIVE
PHOSPHORYLATION
A recent meta-analysis study of the reported gene lists has
described the evidences for a shared dysfunction in protein
turnover in the ubiquitin-proteasome system in ALS mouse
models and ALS patients (Saris et al., 2013a). Moreover, con-
stitutive proteasome was decreased in motor neurons at the
pre-symptomatic stage of SOD1G93A (Cheroni et al., 2005), an
alternative processes to decrease aggregate formation, thus an
attempt to neuroprotect motor neurons of preclinical SOD1G93A
mice before the onset of clinical symptoms (Bendotti et al.,
2012). That should be the case of Nedd4 and Fbxw7 expressions
described here, whose encoded molecules have been already cor-
related to neuroprotection in ALS (Nateri et al., 2004; Matsumoto
et al., 2011; Kwak et al., 2012). Moreover, it should be taken into
attention the elevation of Ubc12 in the spinal cord of SOD1G93A
mice at the pre-symptomatic phase (Massignan et al., 2007).
Ubc12 is an ubiquitin E2 ligase that adds NEDD-8 to substrates.
Ubc12 elevation in pre-symptomatic ALS was correlated to a ten-
tative response to protein aggregation (Massignan et al., 2007).
Interestingly, Nedd8 gene was down regulated in our microarray
analysis only in 80 days old mice, possibly representing a failure of
the above described process close to the period of clinical onset.
The down regulation of genes over-representing the oxida-
tive phosphorylation category at both pre-symptomatic ages of
ALS mice seen in this work may be related to the progressive
deteriorations of mitochondrial function and oxidative phospho-
rylation system described at pre-symptomatic ALS phases (Lin
et al., 2009; Chen et al., 2010; Martin, 2010, 2011; Koopman et al.,
2013), thus triggering reactive oxygen species (ROS) production
(Manfredi and Xu, 2005) and motor neuron vulnerability before
the onset of clinical symptoms. It is also interesting to notice
that the TCA was seen as an over-represented GO term (Table
S5, Supplementary material) in the up-regulated 80 days gene
expression list. The TCA cycle is responsible to provide substrate
to oxidative phosphorylation (Koopman et al., 2013) and its up
regulation was previously seen in laser microdissectedmotor neu-
rons from a VEGF model of ALS already in the pre-symptomatic
period (Brockington et al., 2010). All in all, a possible mechanism
of oxidative phosphorylation in the astrocyte-neuronal unit tak-
ing place in pre-symptomatic ALS might amplify motor neuron
vulnerability to ROS damage.
CHEMOKINE SIGNALING PATHWAY AND TIGHT JUNCTION
The up regulation of all genes in the category chemokine sig-
naling pathway in the pathogenesis of ALS is in agreement to
previous publications (Henkel et al., 2006; Zhang et al., 2006;
Rentzos et al., 2007; Kuhle et al., 2009; Sargsyan et al., 2009;
Tateishi et al., 2010; Gupta et al., 2012). The up regulation of
Cxcr4 and Pik3r1 described in this work is an important find-
ing because the genes might be involved in non-autonomous
toxicity in the early phase of ALS (Shideman et al., 2006; Luo
et al., 2007; Manzano et al., 2011). Furthermore, disruption of
blood-brain barrier and blood-spinal cord barrier are described
as early events in ALS, thus impairing neurovascular unit prior
motor neuron degeneration (Garbuzova-Davis et al., 2011, 2012;
Grammas et al., 2011; Miyazaki et al., 2011). Indeed, reduced lev-
els of adhesion molecules and the tight junction proteins zona
occludens-1, occludin and claudin-5 are shown in post mortem
tissue from patients and in ALS animal models (Zhong et al.,
2008; Arhart, 2010; Garbuzova-Davis et al., 2012).
Our KEGG enriched analysis also demonstrated the modula-
tion of tight junction related genes. Of substantial interest, we
might point out the up regulation of Cldn11 at 40 days and the
down regulation of Cldn10 at 80 days pre-symptomatic ALSmice,
in agreement to previous description on differential regulation
of tight junction genes related to specific characteristics of ALS
clinical evolution (Henkel et al., 2009).
It is also important to highlight the particular modulation
of the Kras gene, which has been up regulated at the age of 40
days and down regulated at the age of 80 days. The Kras gene
is an oncogene that was located in the tight junction category
by the KEGG analysis probably due its relation to topography
of invading/proliferating cells in the scenario of neurodegener-
ative processes. Moreover, Kras proteins regulate cell activities
such as proliferation, differentiation, apoptosis, and cell migra-
tion, those taking place in neurodegenerative processes-induced
astroglial/microglial activation as well as expression of inflamma-
tory and neurotrophic/neurotoxic mediators (Rotshenker, 2009).
There is a marked proliferation/activation of both microglia and
astrocytes at specific disease stages in ALS mouse models (Hall
et al., 1998;Weydt et al., 2002) leading to the production of neuro-
protective or pro-inflammatory molecules, which can decrease or
increase the rate of primary motor neuron degeneration, respec-
tively. Taken all together, up regulation of Kras gene at the early
pre-symptomatic phase is in line with the early glial proliferative
and reactivity events that will initiate the toxic triggering of non-
autonomous cells and also the glial neuroprotective mechanisms
to maintain temporarily the motor neurons. Later in that period,
still before neuronal degeneration taking place, Kras gene down
regulation might allow glial cells to drive toxic insult.
ENDOCYTOSIS AND ANTIGEN PROCESSING AND PRESENTATION
Endocytosis was an additional over-represented pathway in the
pre-symptomatic stage of ALS. Genes found before clinical
onset pointing to endocytosis have been related to clathrin-
dependent/independent endocytosis, autophagy and also neu-
rotransmission (Massey et al., 2006; Luo et al., 2007; Kon
and Cuervo, 2010; McMahon and Boucrot, 2011; Elmer and
McAllister, 2012), thus, related to extracellular turnover, repair
of molecular processes and neuroprotection (Le Roy and Wrana,
2005; Doherty and McMahon, 2009; McMahon and Boucrot,
2011; Polymenidou and Cleveland, 2011). Disruption of these
processes has been implicated as a general feature in the
pathogenesis of ALS (Otomo et al., 2012), whereas there is a
lack of information on that issue in pre-symptomatic periods
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(Morimoto et al., 2007; Tian et al., 2011). Clathrin-mediated
endocytosis has a range of different physiological functions,
remarkably the regulation of surface proteins, nutrition, activa-
tion of signaling pathways, protein trafficking and degradation of
membrane components, in fact, mechanisms that might occur at
the pre-symptomatic phases of ALS.
It is likely that the regulation of the genes for the heat
shock proteins Hspa1a and Hspa8 (also known as Hsp70-3 and
Hsc70, respectively), described in our work is related to neuro-
protective events before neurodegeneration, once treatment with
recombinant human Hsp70 was able to both increase lifespan
(Gifondorwa et al., 2007) and decrease neuromuscular junction
denervation (Gifondorwa et al., 2012) in the SOD1G93A mouse
model. This protective role of Hsp70 has been also supported by
other authors (Bruening et al., 1999; Takeuchi et al., 2002; Kieran
et al., 2004). Actually, the increase of Hsc70 in the spinal cord of
transgenic mice at pre-symptomatic ages of disease (Basso et al.,
2009) and the demonstration of ubiquitinated Hsc70-induced
degradation of mutant SOD1 (Urushitani et al., 2004) empha-
sized the possible neuroprotective role of heat shock protein
regulation described in our work.
Furthermore, antigen processing and presentation pathway
was also pointed as enriched among down regulated genes in 40
days old and up regulated genes in 80 days old pre-symptomatic
SOD1G93A mice. Genes presented in 40 and 80 days lists are
mostly related to major histocompatibility complex (MHC) class
I (H2-Bl, H2-K1, H2-Q1, H2-Q10, H2-Q2, H2-Q7, H2-T22, H2-
T23—80 days ALSmice), molecules necessary for peptide loading
(Tap2—80 days ALS mice) and to surface expression (B2m—40
days ALS mice) (Kimura and Griffin, 2000). B2m gene, possibly
via cell surface MHC class I molecules, has been implicated in
the synaptic plasticity at dendrites and axonal regeneration after
peripheral nerve axotomy (Oliveira et al., 2004). It is possible that
the down regulation of B2m in spinal cord from SOD1G93Aat
pre-symptomatic ages is related to axonal and dendritic retrac-
tions and displacement of neuromuscular junction described as
one of the earliest events faced by motor neurons in ALS models
(Fischer et al., 2004). Our findings are in line with a descrip-
tion of down regulation of B2m protein reported in cerebrospinal
fluid of ALS patients (Brettschneider et al., 2008), thus emphasiz-
ing the importance of its regulation in ALS. Additionally, Rfxank
was down regulated at 40 days in our analysis, which is in agree-
ment to a loss of MHC-II neuronal expression concurrent with
abundant MHCII-positive microglia surrounding motor neurons
in the pre-symptomatic SOD1G93A mice (Casas et al., 2013),
thus, interfering with the neuroimmunemodulation mediated by
microglia (Graber et al., 2010; Sanagi et al., 2010). All in all,
dysregulation of genes related to antigen processing and presen-
tation might account for a number of intercellular mechanisms
able to amplify the harmful non-autonomous cell toxicity at the
pre-symptomatic stages of ALS.
LASER MICRODISSECTION OF ASTROCYTES
We performed laser microdissection of GFAP positive astrocytes
from lumbar spinal cord ventral horn of SOD1G93A transgenic
and wild-typemice in the same pre-symptomatic ages of microar-
ray analysis. The use of laser microdissection has been gained
importance in recent years, once it allows specific cell enrichment
from complex tissues, revealing to be a powerful tool in the study
of neurodegenerative disorders in which individual cell types are
known to be differentially involved in disease stages. The advan-
tage of the methodology is the possibility to address molecular
biology in the context of in vivo cellular analysis. The method is
of substantial importance to evaluate changes in the astrocytes,
the glial cell involved remarkably in toxic mechanisms of ALS.
A previous study has employed laser microdissection of astro-
cytes to perform microarray experiments in ALS mouse model
(Ferraiuolo et al., 2011a). The pattern of gene expression was
first evaluated in the lumbar regions of the spinal cord in the
present analysis, thus, taking into account all cell types from
tissue. The depicted pathways represented the state of intercel-
lular interaction in the pre-symptomatic studied periods of the
ALS mouse model. The selected genes to be evaluated in type-
specific cell, which is the case of Ube2i in the laser microdissected
astrocytes described herein, would allow a closer analysis of astro-
cyte participation in the context of the neighbor cell toxicity.
The Ube2i gene was then chosen for further evaluation in astro-
cytes by qPCR because astrocytes exert a non-autonomous cell
toxicity to motor neurons and because SUMOylation pathway
has gained importance in ALS mechanisms recently (for review,
see Dangoumau et al., 2013). Increases of gene expression for
Ube2i were found in enriched astrocytes samples from 40 and
80 days old pre-symptomatic mice, a regulation still not pre-
sented in the literature in that stage of disease, thus, entering in
the context of ALS pathogenesis. In fact, conjugation of small
ubiquitin-like modifier (SUMO) molecules involves a series of
steps, being the ubiquitin conjugating enzyme E2, codified by
Ube2i gene, responsible for the recognition of the target pro-
tein. SUMOylation is involved in the cellular response to oxidative
stress, hypoxia, glutamate excitotoxicity and proteasome impair-
ment, events that have been linked to motor neuron toxicity in
ALS (Xu et al., 2011). Moreover, studies are required to determine
the precise implication of the SUMO pathway in regulating the
balance between cellular adaptive and neuroprotective response
to stress (Fei et al., 2006; Dangoumau et al., 2013) with a spe-
cial importance to motor neuron in the pre-symptomatic stage
of ALS. Nevertheless, as discussed previously in this report, glu-
tamate astroglial excitotoxicity faced by motor neurons in ALS
is also hamfull by the cleavage of EAAT2 in the ventral horn of
the spinal cord (Martin et al., 2007; Foran et al., 2011). The pro-
teolytic fragments may be SUMOylated and accumulated in the
nucleus of astrocytes (Boston-Howes et al., 2006; Foran et al.,
2011) as described in SOD1G93A mice, worsening the gliotoxic
effects of astrocytes to motor neurons (Foran et al., 2011). Taking
together, SUMOylation process and expression of Ube2i might
participate in complex events related to the astrocyte-neuron unit
in ALS, and future works are required to address specific cellular
events.
In conclusion, the present work gives further evidence about
molecular events taking place in the spinal cord from ALS
mouse model before the onset of classical symptoms. The gene
expression changes reflect responses for both neuroprotection
and toxicity at the spinal cord in the evaluated periods. Indeed,
the study of Ube2i expression in astrocytes adds novel insights
for the participation of this cell type on the early mechanisms
in ALS.
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